LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.
Imagine you're building your dream house. You've spent years designing it, and now you need a building permit from the city. The permit application requires you to disclose everything about your plans, especially anything that might pose a safety risk. Let's say you know your design uses a new, untested type of wiring that might not meet code, but you hide this fact from the inspector to get your permit faster. Years later, you decide to sell the house. During the sale, a rival builder discovers your deception. They take you to court, and the judge, upon learning you lied to the permit office, doesn't just make you fix the wiring. The judge declares your entire building permit—and by extension, your Certificate of Occupancy—void. Your house is now legally unlivable and worthless. You lose everything because of that one intentional lie. In the world of inventions, this scenario is called inequitable conduct. Your invention is the house, the patent is your permit, and the uspto is the permit office. If you intentionally deceive the patent examiner to get your patent approved, a court can declare the entire patent unenforceable. It's known as the “death penalty” of patent_law for a reason: it kills the patent, permanently.
The concept of inequitable conduct didn't appear out of thin air. Its roots lie in a much older legal principle called the doctrine of “unclean hands.” This idea, born in the old equity courts of England, is simple: you can't ask a court for help if you yourself have acted unfairly or deceitfully in the matter. You can't show up to court with “unclean hands” and expect a favorable outcome. For centuries, this was a general principle. Its specific application to patent law began to take shape in the 20th century. The landmark U.S. Supreme Court case, Precision Instrument Mfg. Co. v. Automotive Maintenance Machinery Co. (1945), is widely seen as the birth of modern inequitable conduct. The Court found that a patent applicant had submitted false dates and a perjured testimony to overcome a challenge. The Court held that a patent is not just a private agreement but a “privilege which is conditioned by a public purpose.” Because the applicant had abused this privilege with “unfrank and unfair” dealings, their hands were unclean, and the patent could not be enforced. Through the 1970s and 80s, accusations of inequitable conduct became increasingly common in patent lawsuits. It was a powerful weapon for defendants. If you were accused of infringing a patent, you could turn the tables by accusing the patent holder of deceiving the USPTO. This led to what many judges and lawyers called a “plague” of inequitable conduct allegations, with defendants raising the defense in nearly every case. The courts struggled to find a balance, leading to inconsistent and confusing standards. This chaos prompted the U.S. Court of Appeals for the federal_circuit—the nation's top patent court—to step in. In Kingsdown Medical Consultants, Ltd. v. Hollister Inc. (1988), the court tried to raise the bar, ruling that “gross negligence” alone was not enough to prove an intent to deceive. But the plague continued. The standards remained murky until a groundbreaking decision in 2011 completely reshaped the landscape, which we will explore in detail.
The core obligation that gives rise to inequitable conduct is formally written down in the Code of Federal Regulations. The specific rule is 37_cfr_1.56, often called “Rule 56.” This rule establishes the duty of candor and good faith in dealing with the USPTO. The rule states:
“…each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability…”
Let's break that down in plain English:
Rule 56 is the ethical and legal backbone of the patent application process. Violating this duty is what opens the door to a charge of inequitable conduct.
For decades, the legal test for inequitable conduct was a “sliding scale.” A strong showing of materiality could make up for a weaker showing of intent, and vice-versa. This flexibility created uncertainty and encouraged more accusations. The Federal Circuit decided to end this in the 2011 en banc case Therasense, Inc. v. Becton, Dickinson & Co.. This case completely overhauled the doctrine. The court threw out the sliding scale and established a new, much stricter, two-part test. Instead of comparing state laws, which is not applicable here as patent law is federal, a table comparing the standards before and after Therasense is most useful.
| Aspect of Inequitable Conduct | Pre-Therasense Standard | Post-Therasense Standard (Current Law) |
|---|---|---|
| Materiality | Vague standard. Included any information a “reasonable examiner” would consider important. | “But-for” Materiality. The USPTO would not have granted the patent claim if it had known of the withheld information. (A very high bar). |
| Intent | Could be inferred from “gross negligence.” If you *should have known* something was material, a court could infer you intended to deceive. | Specific Intent to Deceive. Must be the “single most reasonable inference” from the evidence. Gross negligence is not enough. |
| Balancing | A “sliding scale” was used. A strong showing of one element could make up for a weaker showing of the other. | No Sliding Scale. Both but-for materiality AND specific intent to deceive must be proven independently by clear and convincing evidence. |
| Overall Impact | Led to a “plague” of allegations, making the defense common and often successful. | Made inequitable conduct a much rarer and harder defense to prove, reserved for truly egregious cases. It is now considered an “atomic bomb” to be used sparingly. |
What this means for you: The Therasense decision was a seismic shift. It's now much harder for an accused infringer to invalidate your patent on inequitable conduct grounds. However, it also means that if inequitable conduct *is* found, it's because the misconduct was severe and unambiguous.
To prove inequitable conduct today, an accuser must prove two things independently: materiality and intent to deceive. Both must be established by clear and convincing evidence, a higher standard of proof than the usual “preponderance of the evidence” in civil cases.
Materiality asks the question: “How important was the information that was withheld or misrepresented?” Under the *Therasense* standard, the information must be “but-for” material.
This is the main test. But-for materiality means that the USPTO would not have allowed the patent claim to issue “but for” the applicant's misconduct. Think of it like this: An applicant is arguing with the patent examiner that their new invention is not obvious. The applicant knows about a scientific article (a piece of prior_art) that directly suggests their invention's key feature. They choose not to show this article to the examiner. The patent is granted. Years later, an accused infringer finds this article. To prove but-for materiality, they must convince a judge that if the examiner had seen that article, they would have rejected the patent claim as obvious. This is a very high bar. It requires a court to step into the shoes of a patent examiner and re-examine the patent application years later. It’s not enough to show the information was “relevant” or “important.” The accuser must prove the patent claim would have been denied.
The *Therasense* court created one, very narrow exception to the but-for test: cases of affirmative egregious misconduct. This applies to actions that are so fundamentally dishonest that they poison the well, regardless of whether the lie was technically “but-for” material. The classic example is filing a deliberately falsified affidavit or declaration to the USPTO. For instance, if an inventor submits a sworn statement with fabricated test data to convince an examiner that their invention works better than a competing product, this is affirmative egregious misconduct. In such cases, the information is considered material without the need to prove the but-for test. This exception is designed to punish and deter outright fraud on the patent office.
This is often the harder element to prove. Intent asks: “What was going on in the applicant's mind?” It's not enough to show that the applicant was careless, sloppy, or made a mistake. The evidence must show they knew about the material information, knew it was material, and made a deliberate decision to withhold it from the USPTO to mislead the examiner.
Because we can't read minds, intent must be proven through circumstantial evidence. However, *Therasense* set a very high standard for what this evidence must show. The key is that intent to deceive cannot be inferred from materiality alone. Just because an applicant withheld a highly material document does not automatically mean they intended to deceive. Perhaps they thought it wasn't relevant, or their attorney made a judgment call in good faith, or it was a simple oversight.
To prove intent, the accused infringer must show that a deceptive intent is the single most reasonable inference that can be drawn from the evidence. Let's go back to our inventor who withheld the scientific article. Suppose the evidence shows:
In this scenario, the single most reasonable inference is that the inventor knew the article was important and deliberately hid it. Now, consider a different scenario. The evidence shows the inventor's company has a database with 10,000 scientific articles, and the problematic article was just one of them. The inventor never personally cited it, and there are no emails discussing it. In this case, while it's *possible* the inventor knew about it and hid it, it's also reasonable to infer they simply missed it or forgot about it. Since deception is not the *single most reasonable* inference, the intent element would fail.
As an inventor or small business owner, the doctrine of inequitable conduct can be terrifying. The good news is that avoiding it is straightforward if you are diligent and honest from day one. This is not about legal gamesmanship; it's about maintaining your integrity.
The *Therasense* decision was intended to bring clarity and stability, but debates continue. One major controversy is whether the standard is now too high. Some critics argue that the “but-for” materiality test allows clever lawyers to withhold very important information as long as they can create a plausible argument that the patent *might* have been granted anyway. They worry that this high bar protects some bad actors who engage in deceptive conduct that doesn't quite meet the stringent test. On the other side, many practitioners believe the *Therasense* standard is essential to protect the patent system. They argue that the pre-Therasense “plague” chilled innovation and communication. Patent attorneys were so afraid of being accused of inequitable conduct that they would flood the USPTO with mountains of irrelevant documents (“burying the examiner”) just to be safe, which wasted time and resources. They contend that the current standard correctly reserves the “death penalty” for only the most egregious, fraud-like behavior.
The biggest change on the horizon is the rise of Artificial Intelligence (AI) in the patent world. AI-powered search tools can now scan millions of documents worldwide in seconds to find prior_art. This raises fascinating new questions for the duty_of_candor:
The courts and the USPTO have not yet provided clear answers to these questions. Over the next decade, we can expect to see test cases that explore the intersection of AI and an inventor's duty of honesty, potentially reshaping what it means to act with candor in the digital age.